Skip to main content
    C

    CONMED Corporation (CNMD)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NYSE

    $48.41
    -0.94 (-1.90%)

    Market Cap: $1.47B

    Last updated: Nov 17, 2026 at 4:10 PM ET

    CONMED Corporation (CNMD) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    CONMED (CNMD) has a market cap of $1.47B and an enterprise value of $2.24B. Its trailing P/E of 10.2x is below its 10-year median of 31.2x. Its share count is down 3.32% from a year earlier.

    Total Valuation

    Enterprise value is 52.21% above the market cap, as debt exceeds cash.

    Market Cap$1.47B
    Enterprise Value$2.24B
    Latest price (Nov 17, 2026)$48.41

    Key Dates

    The next earnings report is expected on Jan 26, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateJan 26, 2027 (expected)
    Last Earnings DateOct 28, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count fell 0.48% in the quarter ended Sep 30, 2026 and shrank 1.52% a year over 2 years.

    Shares Outstanding29.93M
    Shares Change (YoY)-3.32%
    Shares Change (QoQ)-0.48%
    Share Count Growth (2Y CAGR)-1.52%

    Valuation Ratios

    Sales and book value multiples are 1.1x and 1.4x. Its year-end P/E ranged from 8.8x to 51.9x from 2016 to 2025.

    P/E Ratio10.2x
    Forward P/E10.4x
    P/S Ratio1.1x
    Forward P/S1.1x
    P/B Ratio1.4x
    P/FCF Ratio10.9x
    P/OCF Ratio10.1x
    PEG Ratio1.9

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 10.1x EBITDA and 16.7x free cash flow.

    EV / Earnings30.5x
    EV / Sales1.6x
    EV / EBITDA10.1x
    EV / EBIT16.2x
    EV / FCF16.7x

    Price Statistics

    The stock is up 15.15% over 52 weeks and trades 2.56% above its 50-day average.

    Beta (1Y)0.79
    52-Week Change+15.15%
    1-Month Change+5.12%
    3-Month Change-5.54%
    6-Month Change+33.80%
    5-Year Change-69.72%
    10-Year Change+10.73%
    Total Return (1Y)+15.15%
    Total Return (3Y CAGR)-22.76%
    Total Return (5Y CAGR)-18.80%
    Return vs SPY (1Y)+4.14%
    Max Drawdown (1Y)-30.29%
    Max Drawdown (3Y)-71.42%
    Sharpe Ratio (1Y)0.32
    Correlation with SPY (1Y)0.23
    50-Day Average$47.20
    200-Day Average$42.01
    52-Week Range$31.44 to $54.80
    RSI (14 Days)48.7
    Average Volume (20 Days)387.83K

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 1.49x current liabilities, and total debt is 0.77x shareholder equity.

    Current Ratio1.49x
    Quick Ratio0.70x
    Debt / Equity0.77x
    Debt / EBITDA3.73x
    Debt / FCF6.15x
    Interest Coverage4.14x

    Returns and Efficiency

    Return on invested capital is 5.16% over the last 12 months, against a 5-year average of 4.33%.

    Return on Equity (ROE)6.93%
    Return on Assets (ROA)3.19%
    Return on Invested Capital (ROIC)5.16%
    Return on Capital Employed (ROCE)7.50%
    ROE (5Y Average)4.64%
    ROA (5Y Average)2.12%
    ROIC (5Y Average)4.33%
    Asset Turnover0.59x
    Inventory Turnover1.61x
    Receivables Turnover5.78x
    Cash Conversion Cycle228 days

    Taxes

    Income tax took 30.04% of pretax income over the last 12 months.

    Income Tax (TTM)$31.53M
    Effective Tax Rate30.04%

    Scores

    CNMD has an Altman Z-Score of 2.00, in the grey zone from 1.81 to 2.99, and a Piotroski F-Score of 6 of 9, in the average band of 3 to 7.

    Altman Z-Score2.00
    Altman Z ZoneGrey
    Piotroski F-Score6 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $1.37B over the last 12 months is up 1.62% from the 12 months before.

    Revenue$1.37B
    Revenue Growth (YoY)+1.62%
    Gross Profit$788.34M
    Operating Income$135.59M
    Pretax Income$104.96M
    Net Income$73.43M
    EBITDA$218.81M
    EBIT$138.41M
    Reported EPS (TTM)$4.74

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 46.09% of the $2.30B in total assets.

    Cash and Equivalents$47.97M
    Total Debt$815.87M
    Net Debt$767.89M
    Net Debt Per Share$25.66
    Working Capital$223.08M
    Shareholder Equity$1.06B
    Book Value Per Share$35.42
    Tangible Book Value-$293.64M
    Total Assets$2.30B
    Total Liabilities$1.24B

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $13.62M of capital spending, operating cash flow left $132.69M of free cash flow.

    Operating Cash Flow$146.31M
    Capital Expenditures$13.62M
    Free Cash Flow$132.69M
    FCF Per Share$4.43
    Depreciation and Amortization$80.39M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is 9.90%, against a 5-year average of 10.01%.

    Gross Margin57.57%
    Operating Margin9.90%
    Pretax Margin7.67%
    Net Margin5.36%
    EBITDA Margin15.98%
    EBIT Margin10.11%
    FCF Margin9.69%
    Gross Margin (5Y Average)55.17%
    Operating Margin (5Y Average)10.01%
    Net Margin (5Y Average)3.44%

    Growth

    Revenue grew 9.56% a year over 3 years, and EPS 20.27% a year.

    Revenue Growth (3Y CAGR)+9.56%
    Revenue Growth (5Y CAGR)+9.77%
    EPS Growth (3Y CAGR)+20.27%
    EPS Growth (5Y CAGR)+16.37%
    FCF Growth (3Y CAGR)+135.31%
    FCF Growth (5Y CAGR)+23.98%
    Operating Income Growth (3Y CAGR)+13.57%
    Book Value Per Share Growth (2Y CAGR)+12.13%

    Revenue and profit by year

    Dividends and Yields

    CNMD does not pay a dividend. Its free cash flow yield is 9.16%.

    Earnings Yield9.80%
    FCF Yield9.16%
    Buyback Yield3.41%

    Stock Splits

    The last split was a 3-for-2 forward split on Sep 10, 2001.

    Last Split DateSep 10, 2001
    Split TypeForward split
    Split Ratio3:2

    Peer Position

    Against 7 similar companies, CNMD has the 5th highest P/E.

    P/E Ratio10.2x vs 29.3x median
    P/S Ratio1.1x vs 2.9x median
    ROIC5.16% vs -4.71% median
    Revenue Growth (Trailing 4 Quarters, YoY)+1.62% vs +11.95% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 1.85% and EPS growth at 1.50% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+1.85%
    EPS Growth Forecast (2Y CAGR)+1.50%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewFairly valued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About CNMD

    What is CNMD's market cap?

    CONMED has a market cap of $1.47B. Its enterprise value, which adds debt and subtracts cash, is $2.24B.

    What is CNMD's P/E ratio?

    CONMED has a trailing P/E ratio of 10.2x and a forward P/E of 10.4x.

    How many shares of CNMD are outstanding?

    CONMED has 29.93M shares outstanding. The count is down 3.32% from a year earlier.

    Does CNMD pay a dividend?

    No. CONMED does not pay a dividend.

    How much debt does CNMD have?

    CONMED has $815.87M of total debt and $47.97M of cash and equivalents, a net debt position of $767.89M.